**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69559

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Early cardiopulmonary resuscitation on serum levels of myeloperoxidase, soluble ST2, and hypersensitive C-reactive protein in acute myocardial infarction patients**

Hou M *et al*. Early cardiopulmonary resuscitation in AMI

Min Hou, Ya-Ping Ren, Rui Wang, Lin-Xin Lu

**Min Hou, Rui Wang, Lin-Xin Lu,** Department of Emergency, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, Shanxi Province, China

**Min Hou, Ya-Ping Ren, Rui Wang, Lin-Xin Lu,** Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

**Ya-Ping Ren,** Department of Cardiology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan 030032, Shanxi Province, China

**Author contributions:** Hou M and Lu LX analyzed the data and drafted the paper; Wang R revised the chart of the paper; Ren YP and Hou M analyzed the data and revised and finalized the manuscript for publication.

**Supported by** Key R&D Projects in Shanxi Province, China, No. 201903D321184.

**Corresponding author: Lin-Xin Lu, BM BCh, Chief Physician,** Department of Emergency, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, No. 99 Longcheng Street, Xiaodian District, Taiyuan 030001, Shanxi Province, China. llx6477@163.com

**Received:** July 23, 2021

**Revised:** August 22, 2021

**Accepted:** October 14, 2021

**Published online:** December 6, 2021

**Abstract**

BACKGROUND

Prompt and effective cardiopulmonary resuscitation (CPR) can promote the recovery of spontaneous circulation to some extent and can save patients’ lives. The minimum target of cardiac resuscitation is the restoration of spontaneous circulation (ROSC). However, owing to prolonged sudden cardiac arrest, there is relatively high mortality within 24 h after cardiac resuscitation. Moreover, severe cerebral anoxia can deteriorate the prognosis of patients. Therefore, it is important to adopt an effective clinical evaluation of acute myocardial infarct (AMI) patients’ prognosis after cardiac resuscitation for the purpose of prevention and management.

AIM

To investigate early CPR effects on human myeloperoxidase (MPO), soluble ST2 (sST2), and hypersensitive C-reactive protein (hs-CRP) levels in AMI patients.

METHODS

In total, 54 patients with cardiac arrest caused by AMI in our hospital were selected as the observation group, and 50 other patients with AMI were selected as the control group. The differences in serum levels of MPO, sST2, and hs-CRP between the observation group and the control group were tested, and the differences in the serum levels of MPO, sST2, and hs-CRP in ROSC and non-ROSC patients, and in patients who died and in those who survived, were analyzed.

RESULTS

Serum levels of MPO, sST2, hs-CRP, lactic acid, creatine kinase isoenzyme (CK-MB), and cardiac troponin I (cTnI) were significantly higher in the observation group than in the control group (*P* < 0.05). Serum levels of MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI in the observation group were lower after CPR than before CPR (*P* < 0.05). In the observation group, MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI serum levels were lower in ROSC patients than in non-ROSC patients (*P* < 0.05). MPO, sST2, hs-CRP, and lactic acid serum levels of patients who died in the observation group were higher than those of patients who survived (*P* < 0.05). The areas under receiver operating characteristic curve predicted by MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI were 0.616, 0.681, 0.705, 0.704, 0.702, and 0.656, respectively (*P* < 0.05). The areas under receiver operating characteristic curve for MPO, SST2, hs-CRP, and lactic acid to predict death were 0.724, 0.800, 0.689, and 0.691, respectively (*P* < 0.05). Logistic regression analysis showed that MPO, sST2, and hs-CRP were the influencing factors of ROSC [odds ratios = 1.667, 1.589, and 1.409, *P* < 0.05], while MPO, sST2, hs-CRP, and lactic acid were the influencing factors of death (odds ratios = 1.624, 1.525, 1.451, and 1.365, *P* < 0.05).

CONCLUSION

Serum levels of MPO, sST2, hs-CRP, and lactic acid have a certain value in predicting recovery and prognosis of patients with ROSC.

**Key Words:** Acute myocardial infarction; Cardiac arrest; Human myeloperoxidase; Soluble St2; Hypersensitive C-reactive protein; Lactic acid

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Hou M, Ren YP, Wang R, Lu LX. Early cardiopulmonary resuscitation on serum levels of myeloperoxidase, soluble ST2, and hypersensitive C-reactive protein in acute myocardial infarction patients. *World J Clin Cases* 2021; 9(34): 10585-10594

URL: <https://www.wjgnet.com/2307-8960/full/v9/i34/10585.htm>

DOI: https://dx.doi.org/10.12998/wjcc.v9.i34.10585

**Core Tip:** Acute myocardial infarction (AMI) is one of the leading causes of death. Novel cardiac markers have provided an effective method for early diagnosis of AMI. Our study mainly explored the effects of early cardiopulmonary resuscitation on serum levels in AMI patients.

**INTRODUCTION**

Acute myocardial infarction (AMI) is one of the leading causes of death. Therefore, early detection, diagnosis, and treatment are of great significance[1]. The traditional diagnosis of AMI mainly relies on examining myocardial enzyme profiles. However, elevation of markers is usually significant 4 h after AMI, which can lead to misdiagnosis and missed diagnosis of AMI[2].

In recent years, novel cardiac markers have provided an effective method for the early diagnosis of AMI[3]. AMI patients receive treatment with percutaneous coronary intervention to dredge the blocked blood vessel, significantly reducing the incidence of adverse cardiac events[4]. However, many patients eventually succumb to adverse cardiac events due to severe systemic or local cardiac inflammation. To cope with immediate cardiac arrest after AMI, timely cardiopulmonary resuscitation (CPR) is the main approach to shorten the duration of myocardial ischemia and hypoxia, thus improving the prognosis of patients[5]. Our study mainly explored and discussed the effects of early cardiopulmonary resuscitation on serum levels of human myeloperoxidase (MPO), soluble ST2 (sST2), and hypersensitive C-reactive protein (hs-CRP) in patients with cardiac arrest caused by AMI.

**MATERIALS AND METHODS**

***Baseline data of patients***

A total of 54 AMI patients with cardiac arrest who were managed in our hospital from January 2020 to April 2021 were selected as the observation group. The following were the inclusion criteria: (1) diagnosis of AMI based on standards of "Practical Internal Medicine"[6]; (2) meets criteria of cardiac arrest: Loss of consciousness, with or without the disappearance of great artery pulsation, no spontaneous breathing or sighing breathing; (3) time from onset to admission ≤ 6 h; and (4) informed consent obtained from the patient’s family. The following were the exclusion criteria: (1) patients with absolute contraindication to CPR; and (2) those with complications, such as malignancy, liver and kidney dysfunction, and blood system diseases. Fifty patients with AMI were selected as the control group (Table 1).

***Empirical method***

About 10 mL of venous blood from the patients’ elbow was extracted before and after treatment. A 2500 r/min centrifuge with a centrifugation radius of 6 cm was used for 5 min to separate the supernatant. Double antibody sandwich chemiluminescent immunoassay was used to detect the levels of MPO and cardiac troponin I (cTnI). Biotinylated monoclonal MPO- and cTnI-specific antibodies were mixed with serum to form an antigen-antibody complex. Next, streptomycin magnetic beads were added for incubation. The magnetic beads were adsorbed on the electrode surface by the combination of biotin and streptavidin. Electrode voltage promoted the chemiluminescence of the complex and measured the luminescence intensity. Elecsys software was used to automatically calculate MPO contents and high-sensitive cardiac troponin T through the calibration curve. Serum levels of lactic acid, SST2, and hs-CRP were determined using an enzyme-linked immunosorbent assay kit (Shanghai Enzyme Link Industrial Co., Ltd., Shanghai, China). Biochemical indices included creatine kinase isoenzyme (CK-MB), serum creatinine (Scr), blood urea nitrogen (BUN), and the ratio of aspartate aminotransferase to alanine aminotransferase. The Japan 7170A automatic biochemical analyzer was used to detect cTnI using a rapid test kit.

***Treatment method***

The medical staff evaluated and examined the patients’ vital indicators at the scene. CPR was initiated if the patient had no vital signs. We made sure the patient was lying flat when chest compressions were performed. The palms of both hands were placed on the xiphoid process of the patient’s chest with appropriate folding methods, and the pressure applied was vertical to the weight and the strength of the body. The depth of the pressure in adult was a sternum depression of > 5 cm, and the pressure was maintained 30 times in each group with the frequency of 100 times per min. The patients’ airways were kept open, their head and neck were lifted, and any dirt in the mouth was removed. Subsequently, they were provided artificial respiration twice. The patients’ nasal cavities were closed when blowing, and the air was made sufficient to make the patients’ chest rise and fall. The ratio of chest compressions to artificial respiration was 30:2. Restoration of spontaneous circulation (ROSC) was achieved if after cardiac arrest, continuous heartbeat, and breathing resumed within 24 h after treatment.

***Statistical analysis***

SPSS software version 22.0 (Armonk, NY, United States) was used for all statistical analyses. Statistical significance was set at *P* < 0.05. Measurement data conforming to normal distribution were expressed as mean ± SD, and the *t*-test was used to compare groups. Enumeration data were expressed as frequency or percentage, and comparisons between groups were made usingthe*χ*2 test. The predicted value was analyzed by the receiver operating characteristic (ROC) curve. Logistic regression was used for multivariate analysis.

**RESULTS**

***Comparison of serum indices between the observation and control groups***

The serum levels of MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI in the observation group were significantly higher than those in the control group (*P* < 0.05). There was no significant difference in the serum levels of Scr and BUN between the two groups (*P* > 0.05, Table 2).

***Comparison of serum indices in the observation group before and after CPR***

The serum levels of MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI in the observation group after CPR were significantly lower than those before CPR (*P* < 0.05) (Table 3).

***Comparison of serum indices in the observation group between ROSC and non-ROSC patients***

The serum levels of MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI in ROSC patients of the observation group were significantly lower than those of non-ROSC patients (*P* < 0.05) (Table 4).

***Comparison of serum indices in the observation group before CPR between patients who died and survived***

The serum levels of MPO, sST2, hs-CRP, and lactic acid in patients who died in the observation group before CPR were significantly higher than those of patients who survived (*P* < 0.05). However, there was no significant difference in the serum levels of CK-MB and cTnI in the observation group between those patients who died and those who survived (*P* > 0.05) (Table 5).

***Value of serum levels of MPO and sST2 in predicting ROSC and death***

The areas under the ROC curve predicted by MPO, SST2, hs-CRP, lactic acid, CK-MB, and cTnI were 0.616, 0.681, 0.705, 0.704, 0.702, and 0.656, respectively (*P* < 0.05), as shown in Figure 1A, while the specific parameters are shown in Table 6. On the other hand, the areas under the ROC curve for MPO, SST2, hs-CRP, and lactic acid in predicting death were 0.724, 0.800, 0.689, and 0.691, respectively (*P* < 0.05), as shown in Figure 1B, while the specific parameters are shown in Table 7.

***Multivariate analysis results***

Logistic regression analysis was conducted with MPO, sST2, hs-CRP, lactic acid, CK-MB, and cTnI as independent variables and ROSC (or non-ROSC) as the dependent variable. The results showed that MPO, sST2, and hs-CRP were the influencing factors of ROSC [odds ratios (OR) = 1.667, 1.589, and 1.409, respectively, *P* < 0.05] (Table 8). Moreover, logistic regression analysis was conducted with MPO, sST2, and hs-CRP as independent variables, and death (or survival) as the dependent variable. The results showed that MPO, sST2, hs-CRP, and lactic acid were the influencing factors for death (OR = 1.624, 1.525, 1.451, and 1.365, respectively, *P* < 0.05) (Table 9).

**DISCUSSION**

Brain damage in patients with cardiac arrest is usually caused by abnormal blood flow resulting in systemic ischemia. Since the brain has high oxygen demand and sensitivity to hypoxia, cardiac arrest leads to depolarization of cell membranes and production of free radicals[7,8]. Moreover, free radicals can induce oxidative stress and neuronal damage to a certain extent. Cells will also undergo apoptosis and necrosis, and many metabolites will cross through the blood-brain barrier. Therefore, the prognostic outcome of patients can be evaluated by testing the corresponding serum markers[9-11].

MPO is a type of hemoglobin, an important inflammatory factor, and an important marker of oxidative stress, which plays a significant role in atherosclerosis[12]. Therefore, the increase in MPO will affect the activity of heme oxidase, leading to metabolic disorders of hemoglobin. This further affects the blood oxygen saturation and contributes to the deterioration of an AMI patient’s condition[13]. As a member of the interleukin-1 receptor superfamily, sST2 is mainly expressed in mast cells. In Th2 cells and fibroblasts, its role is mainly for immunomodulatory functions in various inflammatory processes[14,15].

Our study showed that serum levels of MPO and sST2 in AMI patients were significantly higher than those in the control group. Moreover, the levels of MPO and sST2 were significantly decreased after CPR, indicating that MPO and sST2 may participate in the occurrence and development of AMI. Furthermore, *in vivo* MPO reduces the utilization of nitric oxide in the body, promotes the oxidation of low-density lipoprotein, and accelerates the deposition of cholesterol in the blood vessel wall. These promote endothelial dysfunction, leading to the formation of unstable plaques and adverse cardiovascular events, wherein inflammation is significantly increased. In contrast, after CPR, the blood oxygen saturation, immune inflammation, MPO, and sST2 levels are significantly reduced.

Hs-CRP, an acute-phase protein synthesized by the liver, can chemically attract monocytes, induce the production of tissue factors, and promote thrombin[16]. Meanwhile, CRP is also a chemokine of fibrinogen, which enables macrophages to adhere to the endothelial surface and transplant to the intima, causing reactive T lymphocytes accumulation, enhanced platelet activity, imbalance of coagulation and fibrinolysis systems, and promotion of arterial thrombosis. All these mechanisms can lead to instability and rupture of atherosclerotic plaques, leading to acute coronary syndrome[17].

CK-MB and cTnI are the main clinical indicators of myocardial injury examination and have a certain reference value in predicting the degree of myocardial ischemia injury. The combined detection of the two can improve early diagnosis rate and degree monitoring in the treatment process[18,19]. Lactic acid is the final product of human anaerobic glycolysis. When tissues are starved of oxygen, they undergo anaerobic metabolism, resulting in elevated levels of lactic acid in the patient’s blood, which can indicate the extent of brain damage[20].

In our study, the serum levels of sST2, hs-CRP, lactic acid, CK-MB, and cTnI in the observation group were significantly higher than those in the control group (*P* < 0.05). These indices decreased after CPR (*P* < 0.05). In addition, the levels of serum MPO, hs-CRP, lactic acid, CK-MB, and cTnI in ROSC patients were significantly lower than those in non-ROSC patients (*P* < 0.05). The analysis suggests that the myocardium of patients with myocardial infarction has different degrees of damage, coagulation dysfunction, secondary brain injury, cardiac insufficiency, and other symptoms. Therefore, the serum levels of sST2, hs-CRP, lactic acid, CK-MB, and cTnI increased accordingly. When CPR was performed and ROSC occurred, brain injury and myocardial ischemia injury symptoms improved, myocardial contractility significantly increased, and myocardial indices significantly decreased. Thus, serum indicators have a higher value in predicting ROSC and death. Multivariate analysis results showed that MPO, sST2, and hs-CRP were the influencing factors of ROSC, and MPO, SST2, hs-CRP, and lactic acid were the influencing factors of patients’ death, and this is consistent with the findings of previous reports. Thus, these serum indicators could be used as important predictors in clinical research.

Currently, there are no clinical studies that report on changes in serum MPO, sST2, hs-CRP, lactic acid, among others in patients with AMI who had cardiac arrest and CPR. Our study suggests using these objective laboratory indicators to predict ROSC recovery and clinical prognosis of patients with AMI who had CPR.

The limitations of our study include a lack of in-depth research on the corresponding mechanism and its relatively small sample size. Therefore, further in-depth multi-center research with large samples is recommended.

**CONCLUSION**

The levels of serum MPO, sST2, hs-CRP, and lactic acid were significantly decreased in patients with cardiac arrest caused by AMI after CPR. Moreover, MPO, sST2, hs-CRP, and lactic acid had a certain value in predicting the recovery and prognosis of patients with ROSC.

**ARTICLE HIGHLIGHTS**

***Research background***

The minimum target of cardiac resuscitation is the restoration of spontaneous circulation.

***Research motivation***

Effective clinical evaluation of the prognosis of patients with acute myocardial infarction (AMI) after cardiac resuscitation is of great significance.

***Research objectives***

This study aimed to explore the effect of cardiopulmonary resuscitation (CPR) on the levels of myeloperoxidase (MPO), soluble ST2 (sST2), and hypersensitive C-reactive protein (hs-CRP) in patients with AMI.

***Research methods***

A total of 54 AMI patients with cardiac arrest who were managed in our hospital were selected as the observation group. Fifty patients with AMI were selected as the control group.

***Research results***

Serum levels of MPO, sST2, hs-CRP, lactic acid, creatine kinase isoenzyme, and troponin I were significantly higher in the observation group than in the control group (*P* < 0.05).

***Research conclusions***

MPO, sST2, hs-CRP, and lactic acid had a certain value in predicting the recovery and prognosis of patients with restoration of spontaneous circulation.

***Research perspectives***

Further in-depth multi-center research with large samples is recommended.

**REFERENCES**

1 **Jensen MT**. Resting heart rate and relation to disease and longevity: past, present and future. *Scand J Clin Lab Invest* 2019; **79**: 108-116 [PMID: 30761923 DOI: 10.1080/00365513.2019.1566567]

2 **Levy B**, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, Quenot JP, Kimmoun A, Cariou A, Lassus J, Harjola VP, Meziani F, Louis G, Rossignol P, Duarte K, Girerd N, Mebazaa A, Vignon P; Collaborators. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. *J Am Coll Cardiol* 2018; **72**: 173-182 [PMID: 29976291 DOI: 10.1016/j.jacc.2018.04.051]

3 **Wojciechowska A**, Braniewska A, Kozar-Kamińska K. MicroRNA in cardiovascular biology and disease. *Adv Clin Exp Med* 2017; **26**: 865-874 [PMID: 29068585 DOI: 10.17219/acem/62915]

4 **Benedek T**, Popovici MM, Glogar D. Extracorporeal Life Support and New Therapeutic Strategies for Cardiac Arrest Caused by Acute Myocardial Infarction - a Critical Approach for a Critical Condition. *J Crit Care Med (Targu Mures)* 2016; **2**: 164-174 [PMID: 29967856 DOI: 10.1515/jccm-2016-0025]

5 **Kapur NK**, Thayer KL, Zweck E. Cardiogenic Shock in the Setting of Acute Myocardial Infarction. *Methodist Debakey Cardiovasc J* 2020; **16**: 16-21 [PMID: 32280413]

6 **Zeymer U**. [Diagnosis and initial management of acute myocardial infarction]. *MMW Fortschr Med* 2019; **161**: 34-36 [PMID: 30830611 DOI: 10.1007/s15006-019-0223-3]

7 **Wang Y**, Wang M, Ni Y, Liang B, Liang Z. Can Systemic Thrombolysis Improve Prognosis of Cardiac Arrest Patients During Cardiopulmonary Resuscitation? A Systematic Review and Meta-Analysis. *J Emerg Med* 2019; **57**: 478-487 [PMID: 31594741 DOI: 10.1016/j.jemermed.2019.07.011]

8 **Jacobs I**, Nadkarni V, Bahr J, Berg RA, Billi JE, Bossaert L, Cassan P, Coovadia A, D’Este K, Finn J, Halperin H, Handley A, Herlitz J, Hickey R, Idris A, Kloeck W, Larkin GL, Mancini ME, Mason P, Mears G, Monsieurs K, Montgomery W, Morley P, Nichol G, Nolan J, Okada K, Perlman J, Shuster M, Steen PA, Sterz F, Tibballs J, Timerman S, Truitt T, Zideman D; International Liaison Committee on Resuscitation; American Heart Association; European Resuscitation Council; Australian Resuscitation Council; New Zealand Resuscitation Council; Heart and Stroke Foundation of Canada; InterAmerican Heart Foundation; Resuscitation Councils of Southern Africa; ILCOR Task Force on Cardiac Arrest and Cardiopulmonary Resuscitation Outcomes. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Councils of Southern Africa). *Circulation* 2004; **110**: 3385-3397 [PMID: 15557386 DOI: 10.1161/01.CIR.0000147236.85306.15]

9 **Huang Y**, Gao X, Zhou X, Xie B, Zhang Y, Zhu J, Zhu S. Mitophagy in the Hippocampus Is Excessive Activated After Cardiac Arrest and Cardiopulmonary Resuscitation. *Neurochem Res* 2020; **45**: 322-330 [PMID: 31773373 DOI: 10.1007/s11064-019-02916-z]

10 **He Y**, Liu B, Yao P, Shao Y, Cheng Y, Zhao J, Wu J, Zhao ZW, Huang W, Christopher TA, Lopez B, Ma X, Cao Y. Adiponectin inhibits cardiac arrest/cardiopulmonary resuscitation‑induced apoptosis in brain by increasing autophagy involved in AdipoR1‑AMPK signaling. *Mol Med Rep* 2020; **22**: 870-878 [PMID: 32468051 DOI: 10.3892/mmr.2020.11181]

11 **Singla I**, Hreybe H, Saba S. Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction. *Indian Pacing Electrophysiol J* 2008; **8**: 5-13 [PMID: 18270598]

12 **Zeindler J**, Angehrn F, Droeser R, Däster S, Piscuoglio S, Ng CKY, Kilic E, Mechera R, Meili S, Isaak A, Weber WP, Muenst S, Soysal SD. Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer. *Breast Cancer Res Treat* 2019; **177**: 581-589 [PMID: 31267330 DOI: 10.1007/s10549-019-05336-3]

13 **Ooi JD**, Jiang JH, Eggenhuizen PJ, Chua LL, van Timmeren M, Loh KL, O’Sullivan KM, Gan PY, Zhong Y, Tsyganov K, Shochet LR, Ryan J, Stegeman CA, Fugger L, Reid HH, Rossjohn J, Heeringa P, Holdsworth SR, Peleg AY, Kitching AR. A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity. *Nat Commun* 2019; **10**: 3392 [PMID: 31358739 DOI: 10.1038/s41467-019-11255-0]

14 **Scheirlynck E**, Dejgaard LA, Skjølsvik E, Lie OH, Motoc A, Hopp E, Tanaka K, Ueland T, Ribe M, Collet C, Edvardsen T, Droogmans S, Cosyns B, Haugaa KH. Increased levels of sST2 in patients with mitral annulus disjunction and ventricular arrhythmias. *Open Heart* 2019; **6**: e001016 [PMID: 31168386 DOI: 10.1136/openhrt-2019-001016]

15 **Zahler D**, Rozenfeld KL, Stein M, Milwidsky A, Berliner S, Banai S, Arbel Y, Shacham Y. C-reactive protein velocity and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention. *J Nephrol* 2019; **32**: 437-443 [PMID: 30706372 DOI: 10.1007/s40620-019-00594-2]

16 **Kang DO**, Park Y, Seo JH, Jeong MH, Chae SC, Ahn TH, Jang WY, Kim W, Park EJ, Choi BG, Na JO, Choi CU, Kim EJ, Rha SW, Park CG, Seo HS; KAMIR-NIH Registry Investigators. Time-dependent prognostic effect of high sensitivity C-reactive protein with statin therapy in acute myocardial infarction. *J Cardiol* 2019; **74**: 74-83 [PMID: 30745001 DOI: 10.1016/j.jjcc.2018.12.022]

17 **Dell’anna AM**, Bini Viotti J, Beumier M, Orbegozo-Cortes D, Donadello K, Scolletta S, Vincent JL, Taccone FS. C-reactive protein levels after cardiac arrest in patients treated with therapeutic hypothermia. *Resuscitation* 2014; **85**: 932-938 [PMID: 24746786 DOI: 10.1016/j.resuscitation.2014.04.003]

18 **Oh SH**, Kim YM, Kim HJ, Youn CS, Choi SP, Wee JH, Kim SH, Jeong WJ, Park KN. Implication of cardiac marker elevation in patients who resuscitated from out-of-hospital cardiac arrest. *Am J Emerg Med* 2012; **30**: 464-471 [PMID: 21296527 DOI: 10.1016/j.ajem.2010.12.022]

19 **Song L**, Zhang D, Guo C, Gu Z, Wang L, Yao YS, Wang H, Zeng Z, Wang W, Yang Y, Bei W, Rong X, Guo J. The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease. *Biomed Pharmacother* 2021; **137**: 111343 [PMID: 33761594 DOI: 10.1016/j.biopha.2021.111343]

20 **Rubinfeld GD**, Smilowitz NR, Berger JS, Newman JD. Association of Thrombocytopenia, Revascularization, and In-Hospital Outcomes in Patients with Acute Myocardial Infarction. *Am J Med* 2019; **132**: 942-948.e5 [PMID: 31034804 DOI: 10.1016/j.amjmed.2019.04.003]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Bethune Hospital in Shanxi Institutional Review Board.

**Informed consent statement:** All study participants provided informed written consent.

**Conflict-of-interest statement:** None conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:**Unsolicited article; Externally peer reviewed.

**Peer-review started:** July 23, 2021

**First decision:** August 19, 2021

**Article in press:** October 14, 2021

**Specialty type:** Emergency Medicine

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Reyher C **S-Editor:** Wang JL **L-Editor:** Filipodia **P-Editor:** Wang JL

**Figure Legends**



**Figure 1 Receiver operating characteristic curve parameters for predicting restoration of spontaneous circulation and mortality.** A: Restoration of spontaneous circulation; B: Mortality. MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I.

**Table 1 Comparison of baseline data between the observation group and the control group, *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinical data** | **Observation group (*n* = 54)** | **Control group (*n* = 50)** | ***t*/*χ*2** | ***P* value** |
| Male / female | 32/22 | 31/19 | 0.082 | 0.775 |
| Age (yr) | 56.60 ± 6.67 | 57.12 ± 7.10 | -0.385 | 0.701 |
| Body mass index (kg/m2) | 22.19 ± 2.03 | 22.03 ± 2.17 | 0.389 | 0.698 |
| Smoking | 34 (62.96) | 32 (64.00) | 0.012 | 0.913 |
| Hypertension | 33 (61.11) | 29 (58.00) | 0.104 | 0.747 |
| Diabetes | 16 (29.63) | 17 (34.00) | 0.229 | 0.632 |
| Hyperlipidemia | 20 (37.04) | 15 (30.00) | 0.576 | 0.448 |

**Table 2 Comparison of serum indices between the observation group and the control group**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index** | **Control group (*n* = 54)** | **Control group (*n* = 50)** | ***t*** | ***P* value** |
| MPO (ng/L) | 2.95 ± 0.89 | 2.01 ± 0.92 | 5.295 | 0.000 |
| sST-2 (μg/L) | 115.50 ± 21.10 | 96.60 ± 17.22 | 4.981 | 0.000 |
| hs-CRP (mg/L) | 3.76 ± 0.97 | 2.67 ± 0.87 | 6.015 | 0.000 |
| Lactic acid (mmol/L) | 5.77 ± 0.88 | 5.02 ± 0.92 | 4.249 | 0.000 |
| CK-MB (U/L) | 76.39 ± 8.28 | 65.50 ± 12.21 | 5.358 | 0.000 |
| cTnI (μg/L) | 4.59 ± 0.82 | 3.83 ± 0.90 | 4.506 | 0.000 |
| Scr (μmol/L) | 78.29 ± 21.12 | 74.40 ± 19.18 | 0.981 | 0.329 |
| BUN (mmol/L) | 6.70 ± 1.00 | 6.92 ± 1.04 | -1.100 | 0.274 |
| AST (U/L) | 32.20 ± 9.29 | 34.40 ± 8.15 | -1.279 | 0.204 |
| ALT (U/L) | 29.38 ± 5.60 | 30.10 ± 5.12 | -0.683 | 0.496 |
| TC (mmol/L) | 4.20 ± 0.92 | 4.10 ± 0.98 | 0.537 | 0.593 |
| TG (mmol/L) | 1.30 ± 0.32 | 1.35 ± 0.39 | -0.717 | 0.475 |
| HDL-C (mmol/L) | 1.31 ± 0.29 | 1.35 ± 0.30 | -0.691 | 0.491 |
| LDL-C (mmol/L) | 2.24 ± 0.82 | 2.44 ± 0.91 | -1.179 | 0.241 |

MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I; Scr: Serum creatinine; BUN: Blood urea nitrogen; AST: Aspartate aminotransferase ALT: Alanine aminotransferase; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein; LDL-C: Low-density lipoprotein.

**Table 3 Comparison of serum indices such as myeloperoxidase and soluble ST2 in the observation group before and after cardiopulmonary resuscitation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index** | **Before CPR (*n* = 54)** | **After CPR (*n* = 54)** | ***t*** | ***P* value** |
| MPO (ng/L) | 2.95 ± 0.89 | 2.30 ± 0.90 | 3.701 | 0.000 |
| sST-2 (μg/L) | 115.50 ± 21.10 | 105.54 ± 17.89 | 2.586 | 0.011 |
| hs-CRP (mg/L) | 3.76 ± 0.97 | 3.01 ± 0.95 | 3.979 | 0.000 |
| Lactic acid (mmol/L) | 5.77 ± 0.88 | 5.15 ± 0.82 | 3.709 | 0.000 |
| CK-MB (U/L) | 76.39 ± 8.28 | 70.40 ± 11.16 | 3.124 | 0.002 |
| cTnI (μg/L) | 4.59 ± 0.82 | 4.02 ± 0.97 | 3.244 | 0.002 |

CPR: Cardiopulmonary resuscitation; MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I.

**Table 4 Comparison of serum indices such as myeloperoxidase and soluble ST2 in the observation group between the restoration of spontaneous circulation patients and non-restoration of spontaneous circulation patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index** | **ROSC group (*n* = 24)** | **Non-ROSC group (*n* = 30)** | ***t*** | ***P* value** |
| MPO (ng/L) | 2.71 ± 0.42 | 3.14 ± 0.47 | -3.500 | 0.001 |
| sST-2 (μg/L) | 110.20 ± 15.65 | 119.90 ± 17.05 | -2.154 | 0.036 |
| hs-CRP (mg/L) | 3.54 ± 0.72 | 3.97 ± 0.82 | -2.020 | 0.049 |
| Lactic acid (mmol/L) | 5.52 ± 0.70 | 5.98 ± 0.63 | -2.538 | 0.014 |
| CK-MB (U/L) | 74.43 ± 6.50 | 78.38 ± 7.10 | -2.108 | 0.040 |
| cTnI (μg/L) | 4.41 ± 0.70 | 4.81 ± 0.65 | -2.172 | 0.034 |

ROSC: Restoration of spontaneous circulation; MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I.

**Table 5 Comparison of serum indices such as myeloperoxidase and soluble ST2 in the observation group between the patients who died and survived before cardiopulmonary resuscitation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Index** | **Death (*n* = 35)** | **Survival (*n* = 19)** | ***t*** | ***P* value** |
| MPO (ng/L) | 3.11 ± 0.58 | 2.64 ± 0.68 | 2.676 | 0.010 |
| sST-2 (μg/L) | 120.02 ± 15.30 | 106.83 ± 16.10 | 2.971 | 0.004 |
| hs-CRP (mg/L) | 3.89 ± 0.59 | 3.50 ± 0.60 | 2.306 | 0.025 |
| Lactic acid (mmol/L) | 5.69 ± 0.80 | 5.19 ± 0.74 | 2.250 | 0.029 |
| CK-MB (U/L) | 74.82 ± 6.82 | 73.68 ± 7.05 | 0.580 | 0.565 |
| cTnI (μg/L) | 4.62 ± 0.78 | 4.53 ± 0.69 | 0.421 | 0.675 |

MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I.

**Table 6 Receiver operating characteristic curve parameters for predicting restoration of spontaneous circulation**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Area under curve** | ***P* value** | **Cut off value** | **Sensitivity (%)** | **Specificity (%)** |
| MPO | 0.616 | 0.039 | 3.50 | 40.70 | 79.60 |
| sST-2 | 0.681 | 0.001 | 121.69 | 55.90 | 79.60 |
| hs-CRP | 0.705 | 0.000 | 3.93 | 64.40 | 75.50 |
| Lactic acid | 0.704 | 0.000 | 5.76 | 78.00 | 63.30 |
| CK-MB | 0.702 | 0.000 | 76.96 | 55.90 | 77.60 |
| cTnI | 0.656 | 0.005 | 3.98 | 86.40 | 44.90 |

MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein; CK-MB: Creatine kinase isoenzyme; cTnI: Cardiac troponin I.

**Table 7 Receiver operating characteristic curve parameters for predicting mortality**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Area under curve** | ***P* value** | **Cut off value** | **Sensitivity (%)** | **Specificity (%)** |
| MPO | 0.724 | 0.000 | 3.36 | 54.90 | 86.50 |
| sST-2 | 0.800 | 0.000 | 114.52 | 60.60 | 91.90 |
| hs-CRP | 0.689 | 0.001 | 3.48 | 73.20 | 64.90 |
| Lactic acid | 0.691 | 0.001 | 5.39 | 64.80 | 70.30 |

MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein.

**Table 8 Logistic regression analysis of restoration of spontaneous circulation factors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Factor** | **** | **SE** | **Walds** | ***P* value** | **OR (95%CI)** |
| MPO | 0.511 | 0.194 | 6.938 | 0.000 | 1.667 (1.140-2.438) |
| sST-2 | 0.463 | 0.135 | 11.762 | 0.000 | 1.589 (1.219-2.070) |
| hs-CRP | 0.343 | 0.112 | 9.379 | 0.000 | 1.409 (1.131-1.755) |

OR: Odds ratios; MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein.

**Table 9 Logistic regression analysis of death factors**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Factor** | **** | **SE** | **Walds** | ***P* value** | **OR (95%CI)** |
| MPO | 0.485 | 0.182 | 7.101 | 0.000 | 1.624 (1.137-2.320) |
| sST-2 | 0.422 | 0.121 | 12.163 | 0.000 | 1.525 (1.203-1.933) |
| hs-CRP | 0.372 | 0.109 | 11.648 | 0.000 | 1.451 (1.172-1.796) |
| lactic acid | 0.311 | 0.123 | 6.393 | 0.000 | 1.365 (1.072-1.737) |

OR: Odds ratios; CI: Confidence interval; MPO: Myeloperoxidase; sST2: Soluble ST2; hs-CRP: Hypersensitive C-reactive protein.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**